835 related articles for article (PubMed ID: 23440694)
1. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
2. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
3. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
Nandi A; Pal P; Basu S
Rheumatol Int; 2019 Oct; 39(10):1797-1801. PubMed ID: 31302740
[TBL] [Abstract][Full Text] [Related]
4. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Huang CF; Wang L; Hwang KP; Yang KD
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S; Kawashima H; Kashiwagi Y; Hoshika A
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
Shao S; Zhou K; Liu X; Liu L; Wu M; Deng Y; Duan H; Li Y; Hua Y; Wang C
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4210-e4220. PubMed ID: 33837779
[TBL] [Abstract][Full Text] [Related]
7. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Lai TJ; Tang CW; Lin CC; Ho TY; Liou HH; Ger LP
J Chin Med Assoc; 2013 Aug; 76(8):438-45. PubMed ID: 23769880
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H; Suzuki H; Abe J; Suzuki Y; Suenaga T; Takeuchi T; Yoshikawa N; Shibuta S; Miyawaki M; Oishi K; Yamaga H; Aoyagi N; Iwahashi S; Miyashita R; Honda T; Onouchi Y; Terai M; Hata A
Cytokine; 2012 Dec; 60(3):681-5. PubMed ID: 22944461
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR; Zhao HZ; Chang LJ; Xu X; Gao Y; Li M; Kong QY; Wang MM; Zhao CF
Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[TBL] [Abstract][Full Text] [Related]
13. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
15. Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease.
Duan Y; Li H; Luo D; Jiang J; Liu B; Li G
Int Immunopharmacol; 2023 Sep; 122():110600. PubMed ID: 37423157
[TBL] [Abstract][Full Text] [Related]
16. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
17. Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease.
Gong F; Zhang Y; Xie C; Zhu W; Wang W; Fu S; Shen H
Pediatr Res; 2012 Jun; 71(6):720-4. PubMed ID: 22337222
[TBL] [Abstract][Full Text] [Related]
18. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
19. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
Doi M; Takeda T; Sakurai Y; Kato J; Hayashi T; Fukuda K; Takase T; Shima M
J Investig Allergol Clin Immunol; 2010; 20(5):413-8. PubMed ID: 20945608
[TBL] [Abstract][Full Text] [Related]
20. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
Huang XB; Zhao S; Liu ZY; Xu YY; Deng F
Ann Med; 2023; 55(2):2264315. PubMed ID: 37870383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
